Dr. Eric Simoes, MD
Pediatric Infectious Disease (Pediatric Infectious Diseases Physician)
13123 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Colorado since 1990, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Infectious Diseases Physician primary
CO license 30006 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 74 payments worth $180,394 in total to this clinician.
| Pfizer Inc. | $96,072 |
|---|---|
| Merck Sharp & Dohme LLC | $68,452 |
| AstraZeneca Pharmaceuticals LP | $10,885 |
| Sanofi Pasteur Inc. | $3,685 |
| GlaxoSmithKline, LLC. | $1,300 |
| Consulting Fee | $68,114 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $63,369 |
| Travel and Lodging | $47,533 |
| Food and Beverage | $1,378 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $25,520 |
| Pfizer Inc. Sep 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bangkok, Thailand · in-kind | $15,887 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging travel to Riyadh, Saudi Arabia · in-kind | $12,523 |
| Merck Sharp & Dohme LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $11,020 |
| Pfizer Inc. Nov 24, 2025 | Consulting Fee PREVNAR 20 · VACCINES | $10,450 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee ABRYSVO · VACCINES | $10,450 |
| Pfizer Inc. May 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bucharest, Romania · in-kind | $9,410 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $6,960 |
| Pfizer Inc. Jun 9, 2025 | Consulting Fee ABRYSVO · VACCINES | $6,500 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,210 |
All 55 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $361 |
| Pfizer Inc. Nov 24, 2025 | Consulting Fee PREVNAR 20 · VACCINES | $10,450 |
| Pfizer Inc. Nov 24, 2025 | Consulting Fee PREVNAR 20 · VACCINES | $4,550 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $25,520 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Travel and Lodging travel to Riyadh, Saudi Arabia Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee ABRYSVO · VACCINES | $10,450 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee ABRYSVO · VACCINES | $5,200 |
| Pfizer Inc. Sep 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bangkok, Thailand · in-kind | $15,887 |
| Pfizer Inc. Sep 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bangkok, Thailand · in-kind | $570 |
| Pfizer Inc. Sep 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bangkok, Thailand · in-kind | $125 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $5,220 |
| Pfizer Inc. Sep 17, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to El Paso, TX · in-kind | $233 |
| Pfizer Inc. Sep 17, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to El Paso, TX · in-kind | $223 |
| Merck Sharp & Dohme LLC Sep 17, 2025 | Travel and Lodging travel to Philadelphia, PA Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging travel to Riyadh, Saudi Arabia · in-kind | $12,523 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging travel to Riyadh, Saudi Arabia · in-kind | $1,635 |
| Merck Sharp & Dohme LLC Sep 12, 2025 | Travel and Lodging travel to Riyadh, Saudi Arabia · in-kind | $415 |
| Pfizer Inc. Sep 4, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to El Paso, TX · in-kind | $592 |
| Merck Sharp & Dohme LLC Sep 4, 2025 | Travel and Lodging ENFLONSIA · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $254 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Travel and Lodging ENFLONSIA · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $1,074 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Travel and Lodging ENFLONSIA · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $109 |
| Pfizer Inc. Sep 2, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $4,125 |
| Merck Sharp & Dohme LLC Sep 2, 2025 | Travel and Lodging ENFLONSIA · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $214 |
| Sanofi Pasteur Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) BEYFORTUS · Vaccines | $2,345 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $611 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $70.00 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $35.00 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $22.05 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $22.05 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $22.05 |
| Pfizer Inc. Aug 15, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $22.05 |
| Pfizer Inc. Aug 12, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to El Paso, TX · in-kind | $414 |
| Pfizer Inc. Aug 12, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $145 |
| Pfizer Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $4,125 |
| Pfizer Inc. Jul 29, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Albuquerque, NM · in-kind | $314 |
| Pfizer Inc. Jul 16, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $692 |
| Pfizer Inc. Jul 7, 2025 | Consulting Fee PREVNAR 13 · VACCINES | $3,250 |
| Pfizer Inc. Jul 7, 2025 | Consulting Fee PREVNAR 13 · VACCINES | $1,950 |
| Pfizer Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $299 |
| Pfizer Inc. Jul 1, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $330 |
| Pfizer Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $4,125 |
| Pfizer Inc. Jun 25, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $3,150 |
| Pfizer Inc. Jun 20, 2025 | Consulting Fee ABRYSVO · VACCINES | $5,749 |
| Pfizer Inc. Jun 9, 2025 | Consulting Fee ABRYSVO · VACCINES | $6,500 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $6,960 |
| Pfizer Inc. Jun 3, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Sandy, UT · in-kind | $341 |
| Pfizer Inc. May 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bucharest, Romania · in-kind | $9,410 |
| Pfizer Inc. May 27, 2025 | Travel and Lodging ABRYSVO · VACCINES · travel to Bucharest, Romania · in-kind | $780 |
| Sanofi Pasteur Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) BEYFORTUS · Vaccines | $1,340 |
| Merck Sharp & Dohme LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made to Third Party Organization not to Physician. | $11,020 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $2,610 |
| Merck Sharp & Dohme LLC Mar 24, 2025 | Travel and Lodging travel to Iguazu Falls, Brazil Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
| AstraZeneca Pharmaceuticals LP Mar 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $6,210 |
| GlaxoSmithKline, LLC. Jan 3, 2025 | Consulting Fee | $1,300 |
| AstraZeneca Pharmaceuticals LP Jan 2, 2025 | Consulting Fee | $4,675 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $572,819 in research payments for these studies, mostly to the institutions running them.
- Prevention of outpatient acute respiratory illness in infants and descriptive epidemiology of rsv in infants and their mothers
Pfizer Inc. - STUDY NAME#A prospective-cohort study to compare the immune response to Respiratory Syncytial Virus and clinical outcomes in patients who received nirsevimab versus those who had natural infection in the prior respira…
Merck Sharp & Dohme LLC - A prospective-cohort study to compare the immune response to Respiratory Syncytial Virus and clinical outcomes in patients who received nirsevimab versus those who had natural infection in the prior respiratory season.
Merck Sharp & Dohme LLC - Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06252285 - A phase 3 study to investigate the safety tolerability and immunogenicity of revaccinating pregnant participants during subsequent pregnancies and persistence of immunity of a single dose of a bivalent respiratory syn…
Pfizer Inc. - A master phase 123 protocol to investigate the safety tolerability and immunogenicity of bivalent BNT162B2 rna based vaccine candidates in healthy children
Pfizer Inc. - A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Merck Sharp & Dohme LLC - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.